The week-ending August 8 saw 20 companies in the healthcare sector report their quarterly earnings. With the earnings season ...

U.S. stocks closed rallied on Friday, with the Nasdaq Composite (COMP:IND) securing another back-to-back record, even as ...

On August 9, Fundstrat’s Tom Lee appeared on CNBC to discuss the current state of the market and the potential for further ...

William “Bill” Joseph Cruser, 80, of Greenwood, IN passed away Tuesday, August 5, 2025, at Community Hospital South in ...

Eli Lilly is seeing strong growth from its weight loss drugs. Investors are nervous about tariffs on drugs and weak data from ...

Indianapolis-based Eli Lilly and Co. shares fell Thursday, Aug. 7 following the pharmaceutical company's second-quarter ...

Eli Lilly is one step closer to bringing an oral weight loss medicine to the booming obesity drug market. A clinical trial ...

Eli Lilly says it plans to apply for U.S. Food and Drug Administration (FDA) approval by the end of the year to market the ...

In May, it announced it would acquire SiteOne Therapeutics, a drugmaker with a promising investigational medicine for pain.

Eli Lilly and Company (LLY) is currently at $634.33, down $6.53 or 1.02% --Would be lowest close since Jan. 25, 2024, when it closed at $627.62 --Worst four day stretch since the four days ending Oct.

In the wake of this sell-off, a critical question arises about whether LLY stock represents a buying opportunity.

The stock is struggling badly, and if things don't improve in short order, Eli Lilly will be on track for its worst ...